PRCT (PROCEPT BioRobotics) Moat Score: 5/10 (As of Jun. 25, 2026)


PRCT PROCEPT BioRobotics Corp PRCT
70 GF Score
Price $20.85
GF Value $91.98
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Moat Score?

PROCEPT BioRobotics PRCT +1.16% 70 Moat Score is 5 as of Jun. 25, 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $91.98 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 846 Medical Devices & Instruments companies, PROCEPT BioRobotics ranks better than 91.13% on this metric.

PROCEPT BioRobotics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

PROCEPT BioRobotics has Narrow Moat: PROCEPT BioRobotics Corp has a solid narrow moat due to its innovative medical technology and patents. However, it faces high R&D costs and competition from larger medical device companies, limiting its moat strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PROCEPT BioRobotics might have Narrow Moat - Solid narrow moat.

PROCEPT BioRobotics  (NAS:PRCT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PROCEPT BioRobotics Moat Score Related Terms

PRCT vs ALMR, AHCO, ENOV: Moat Score Comparison

For the Medical Devices subindustry, PROCEPT BioRobotics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PROCEPT BioRobotics Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Moat Score distribution charts can be found below:

* The bar in red indicates where PROCEPT BioRobotics's Moat Score falls into.


PRCT
70GF Score
PROCEPT BioRobotics Corp PRCT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
PROCEPT BioRobotics (PRCT) has a Moat Score of 5 as of Jun. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PROCEPT BioRobotics ranks #75 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 8.9%.
Is PROCEPT BioRobotics' Moat Score too high?
PROCEPT BioRobotics' current Moat Score is 5. Based on the distribution chart, PROCEPT BioRobotics ranks #75 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Moat Score compare to ALMR and AHCO?
According to the Medical Devices & Instruments industry distribution chart, PROCEPT BioRobotics ranks #75 out of 846 companies for Moat Score. This places PROCEPT BioRobotics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. PROCEPT BioRobotics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $91.98, compared to a current price of $20.85 — trading 77.3% below its estimated fair value. The current Moat Score is 5. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Moat Score is 5 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of $20.85 is trading 77.3% below its estimated GF Value™ of $91.98. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for PRCT:

  • Moat Score: 5
  • GF Value™: $91.98 vs. price of $20.85 (77.3% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:Mexico
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score

Get the complete analysis for PRCT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.85
Price
$91.98
GF Value